ANDA review speeds up
This article was originally published in The Tan Sheet
FDA is approving abbreviated new drug applications at a faster pace in fiscal 2004 than in FY 2003. From October 2003 through August 2004, the agency's Office of Generic Drugs approved 289 original ANDAs - five more than were cleared in all of FY 2003. The agency also tentatively approved 83 applications in the first 11 months of FY 2004, compared to 89 tentative approvals in all of FY 2003. FDA attributes the improvements to increased staff, better training and changes in procedures, which allow reviewers to verbally communicate application deficiencies to sponsors. FDA anticipates that FY 2004 also will show a surge in the total number of generic applications received, as well as a decline in the average review time for ANDAs...
You may also be interested in...
Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”
A Senate Health Committee update hearing on the COVID-19 federal response was noteworthy primarily for demonstrating that FDA Commissioner Stephen Hahn appears to have salvaged the agency’s position as a voice of credibility with a key political constituency – at least for now.
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.